PDF herunterladen
Thromb Haemost 1966; 15(01/02): 118-130
DOI: 10.1055/s-0038-1649416
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Some Effects of Low Molecular Weight Dextran on Coagulation[*]

Marion Dugdale
1   Departments of Medicine and Neurosurgery, University of Tennessee College of Medicine and City of Memphis Hospitals, Memphis, Tennessee.
,
J.D Nofzinger
1   Departments of Medicine and Neurosurgery, University of Tennessee College of Medicine and City of Memphis Hospitals, Memphis, Tennessee.
,
F Murphey
1   Departments of Medicine and Neurosurgery, University of Tennessee College of Medicine and City of Memphis Hospitals, Memphis, Tennessee.
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
27. Juni 2018 (online)

    Lizenzen und Reprints

Summary

LMDX has been shown to affect adversely the rate of prothrombin consumption during coagulation and the structure of the fibrin clot when present in the concentrations usually recommended for clinical use. Its use in animals with hemostatic defects induced by the pump-oxygenator was accompanied by excessive bleeding. At the same time, however, it conferred some form of protection which led to improved survival. A manner of using LMDX so as to benefit from its protective action without endangering hemostasis is currently under study.

* This work was supported in part by USPHS Grant NB-05651.


 

  • References

  • 1 Adelson E. Bleeding time prolongation, after dextran infusion. Bibi, haemat. (Basel) 07: 275 1958;
    PubMedGoogle Scholar
  • 2 Bergentz S. E, Eiken O, Nilsson I. M. The effect of dextran of varions molecular weights on the coagulation in dogs. Thrombos. Diathes. haemorrh. (Stuttg) 06: 151 1961;
    PubMedGoogle Scholar
  • 3 Breckenridge I. M, Walker W. F. Blood loss in open-heart surgery with low-molecular - weight dextran. Lancet I: 1190 1963;
    PubMedGoogle Scholar
  • 4 Carbone J. V, Furth F. W, Scott Jr. R, Crosby W. H. An hemostatic defect associated with dextran infusions. Proc. Soc. exp. Biol. (N. Y) 85: 101 1954;
    CrossrefPubMedGoogle Scholar
  • 5 de Nicola P. Thrombelastography. Charles C. Thomas; Springfield, Ill: 1957
    Google Scholar
  • 6 Fletcher A. P, Alkjaersig N, Sherry S. The maintenance of a sustained thrombolytic state in man. I Induction and effects. J. clin. Invest 38: 1096 1959;
    CrossrefPubMedGoogle Scholar
  • 7 Gaintner J. R, Jackson D. P, Conley C. L. Morphologic studies of clot retraction. Bull. Johns Hopkins Hosp 03: 266 1962;
    PubMedGoogle Scholar
  • 8 Godal H. C. The interaction of protamine with human fibrinogen and the significance of this interaction for the coagulation of fibrinogen. Scand. J. clin Lab. Invest 12: 433 1960;
    CrossrefPubMedGoogle Scholar
  • 9 Graham J. B, Langdell R. D, Brinkhous K. M. Estimation of the rate of prothrombin utilization. In: The Coagulation of Blood: Methods of Study. ed. Tocantins L. M. 117 Grune and Stratton, N. Y.: 1955
    Google Scholar
  • 10 Jacobaeus U. The effect of dextran on the coagulation of blood. Acta med. scand 151: 505 1955;
    PubMedGoogle Scholar
  • 11 Jacobaeus U. Studies on the effect of dextran on the coagulation of blood. Acta med. scand., Suppl.. 322. 1957
    PubMedGoogle Scholar
  • 12 Langdell R. D, Adelson E, Furth F. W, Crosby W. H. Dextran and prolonged bleeding time. J. Amer. med. Ass 166: 346 1958;
    CrossrefPubMedGoogle Scholar
  • 13 Long Jr. D. M, Sanchez L, Varco R. L, Lillehei C. W. The use of low molecular weight dextran and serum albumin as plasma expanders in extracorporeal circulation. Surgery 50: 12-47 1961;
    PubMedGoogle Scholar
  • 14 Long Jr. D. M. The status of plasma expanders in open heart surgery. Dis. Chest 41: 578 1962;
    CrossrefPubMedGoogle Scholar
  • 15 Nilsson I. M, Eiken O. Further studies on the effect of dextran of various molecular weight on the coagulation mechanism. Thrombos. Diathes. haemorrh. (Stuttg) 11: 38 1964;
    PubMedGoogle Scholar
  • 16 Ricketts C. R. Interaction of dextran and fibrinogen. Nature (Lond) 169: 970 1952;
    PubMedGoogle Scholar
  • 17 Rodman Jr. M. F, Barrow E. M, Graham J. B. Diagnosis and control of the hemophilioid states with the partial thromboplastin time (PTT) test. Amer. J. clin. Path 29: 525 1958;
    PubMedGoogle Scholar
  • 18 Ross S. W, Ebert R. V. Microelectrophoresis of blood platelets and the effects of dextran. J. clin. Invest 38: 155 1959;
    CrossrefPubMedGoogle Scholar
  • 19 Sawyer R. B, Moncrief J. A, Ganizaro P. G. Dextran therapy in thrombophlebitis. J. Amer, med. Ass 191: 136 1965;
    CrossrefPubMedGoogle Scholar
  • 20 Scott J. S. Blood coagulation failure in obstetrics. Brit. med. J II: 290 1955;
    PubMedGoogle Scholar
  • 21 Sherry S, Lindemeyer R. I, Fletcher A. P, Alkjaersig N. Studies on enhanced fibrinolytic activity in man. J. clin. Invest 38: 810 1959;
    CrossrefPubMedGoogle Scholar
  • 22 Wells Jr. R. E. Kheology of blood in the micro vasculature. New Engl. J. Med 270: 832-889 1964;
    CrossrefPubMedGoogle Scholar
  • 23 Winfrey III E. W., Foster J. H. Antithrombogenic effect of low molecular weight dextran in small artery surgery. Arch. Surg 88: 78 1964;
    CrossrefPubMedGoogle Scholar